"Coronavirus: Oxford vaccine triggers immune response"

Status
Not open for further replies.
10 February 2021....Excerpt:
....1.2 million doses of the Oxford-AstraZeneca vaccine that will arrive in February and March: 580,000 next week (via a DHL flight) and the remaining quota the following month. These shipments are part of an additional agreement to the one already established by the Government and AstraZeneca, for 22.4 million doses.
 
11 February 2021
Rich countries vs. Poor: The COVID-19 Vaccine Distribution Dilemma. The arrival of the expected coronavirus vaccines is the subject of intense negotiations by all governments. The challenge of Latin America.

The Pan American Health Organization (PAHO) assured that 37 Latin American countries and territories participating in COVAX have already been notified about this first phase of delivery of the vaccine developed by the British laboratory AstraZeneca and the University of Oxford. This tool will send in the first half of the year, between mid-February and the end of June, more than 35 million doses of the vaccine to combat the coronavirus. Many countries celebrate that they already have immunization against COVID-19, but the intention is not to create a sense of security with health measures to continue slowing the spread of the virus. The numbers of the pandemic continue to worsen....
 
12 February 2021
Excerpt:....sources close to the AstraZéneca laboratory assured this newspaper that between Sunday and Tuesday 580,000 new doses will arrive from the Serum Institute of India.
 
12 February 2021
AstraZeneca to produce vaccines for new coronavirus variants. The UK's largest drug manufacturer, AstraZeneca, said it plans to accelerate the adaptation of the coronavirus vaccine it developed with the University of Oxford to new variants of the virus within six to nine months.

While presenting the company's annual balance at a press conference, the company directors announced that in collaboration with the University of Oxford, they will now focus on adapting their vaccine to new strains and hope to reduce the time needed to reach production to scales between six and nine months, using existing clinical data and optimizing their established supply chain.

Although the results of the vaccine showed an efficacy of 76% after the first dose reaching 82% in the second, its effectiveness against the South African variant was reduced to between 10% and 20%. However, the vaccine is still effective against at least one variant of the virus, first discovered in Kent, England. The Oxford/AstraZeneca immunization was recommended by the World Health Organization (WHO) for use in all adults, despite limited data on its efficacy for older people, which led some European countries to rule out its application to those over 65 years. The pharmaceutical giant also announced that it has signed a letter of intent with the German laboratory IDT Biologika to produce more coronavirus vaccines for Europe from the second quarter of this year and ensure long-term supply capacity.

In addition to the vaccine, the company began phase 3 clinical trials of AZD7442, a combination of antibodies for the prevention and treatment of coronavirus....
 
13 January 2021....by Pablo Esteban
Excerpt: ....we must add the 580 thousand from Oxford/AstraZeneca that will arrive next Tuesday. Produced by the Serum Institute of India, they will be transported by the logistics aviation company DHL. In addition, 580,000 more will arrive in March and with that the agreement with the Anglo-Swedish pharmaceutical company sealed by the government days ago to enable the arrival of "additional items" to domestic territory will be fulfilled....

....It is worth noting that, as of March, AstraZeneca will begin with successive shipments of batches to complete the 22.4 million doses committed in August 2020 throughout 2021. In this case, it is the active substance that is being produced by the Argentine laboratory mAbxience (owned by local businessman Hugo Sigman) and which will be packaged and distributed throughout Latin America (except Brazil) by the work of the Liomont Laboratory in Mexico....
 
17 February 2021....by Joaquín Mugica Díaz
By March, the Government will have an Aerolineas Argentinas plane with the capacity to transport up to one million doses.
The reforms on one of the aircraft will culminate in the next two weeks. They could load 600 thousand in the cellar and 400 thousand in the cabin...The national government has a defined objective in health matters: to bring to Argentina as many vaccines as possible. The more doses there are, the more volume the vaccination plan can take in a short time. That longing confronts reality....

Aeronautical sources explained to Infobae that afterwards the amount of vaccines they can load is subject to the way they are wrapped and the size they are. That is, the loads are made based on the volume of the packages, not on the quantities of doses, and therefore the number can be done....Airlines have already made technical inquiries to Airbus, which is the world's leading aircraft manufacturer, to make all the modifications. Then they will need a final approval by the National Civil Aviation Administration (ANAC), which must give the go-ahead to the reforms that were carried out. The plane would be reconfigured with freighter mode.

The Airbus 330 fleet that Aerolineas Argentinas has is made up of 10 aircraft, which are destined to cover international destinations. Two of those ten are dedicated to the task of bringing vaccines to the country, but since there was not much demand, they are always working with the same plane. In other words, the four flights to Russia were with the same airliner. The plane with the LV-GIF license plate is the one that is being modified and will shortly be available for the Government to use in order to bring more doses in a short time. It is part of the logistics plan to improve the supply of vaccines. The first link in the chain to give volume to the vaccination plan designed by Ginés Gonzáles García and his team.
 
Status
Not open for further replies.
Back
Top